首页> 外文期刊>Клиническая медицина >Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from atrerial hypertension with metabolic syndrome
【24h】

Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from atrerial hypertension with metabolic syndrome

机译:巯基和磷酸盐ACE抑制剂对患有代谢综合征的运动性高血压患者血小板凝集的影响的比较评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The purpose of the study was to compare the influence of two ACE inhibitors--captopril, a sulfhydryl one, and fozinopril, a phosphate one--on the aggregation activity of thrombocytes in patients suffering from arterial hypertension (AH) with metabolic syndrome (MS). Sixty-nine patients suffering from AH with MS were examined; 36 patients were administered captopril during 16 weeks, while 33 patients were treated with fozinopril during the same period of time. Changes in anthropometric parameters, blood lipid spectrum, lipid peroxidation in blood plasma and thrombocytes, and the antioxidative protection of liquid part of blood and platelets, as well as the aggregation activity of thrombocytes were assessed. The data received were processed using Student criterion and system multifactor analysis. The study shows that the use of fozinopril in patients with AH and metabolic syndrome attenuates peroxidation syndrome and optimizes thrombocyte aggregation. Prolonged fozinopril application will stabilize the achieved effect. Captopril did not have a positive effect on the parameters under study. In conclusion, fozinopril should be applied in combination with non-drug means to lower body weight in patients suffering from AH with MS.
机译:这项研究的目的是比较两种ACE抑制剂对患有代谢综合征(MS)的动脉高压(AH)患者的血小板聚集活性的影响,巯基普利特是一种巯基,磷酸盐是一种磷。 )。检查了69名患有MS的AH的患者; 36例患者在16周内接受了卡托普利治疗,而33例患者在同一时间接受了fozinopril治疗。评估人体测量学参数,血脂谱,血浆和血小板中脂质过氧化的变化,以及血液和血小板的液体部分的抗氧化保护以及血小板的聚集活性。使用学生准则和系统多因素分析处理接收到的数据。研究表明,在患有AH和代谢综合征的患者中使用fozinopril可减轻过氧化综合征并优化血小板聚集。长期服用fozinopril会稳定效果。卡托普利对所研究的参数没有积极影响。总之,应将fozinopril与非药物手段结合使用,以降低患有MS的AH患者的体重。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号